Back to Search Start Over

Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples

Authors :
Yves Delneste
Norbert Ifrah
Diane Raingeard de la Blétière
Mathilde Hunault-Berger
Marc Zandecki
Anne Coutolleau
Isabelle Luquet
Philippe Guardiola
Laurence Baranger
Pascale Cornillet-Lefebvre
Annaëlle Beucher
Odile Blanchet
Aline Schmidt-Tanguy
Franck Geneviève
BMC, Ed.
Plateforme SNP, Transcriptome & Epigénomique
Centre Hospitalier Universitaire d'Angers (CHU Angers)
PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)
Centre de Recherche en Cancérologie Nantes-Angers (CRCNA)
PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes)
Laboratoire d'hématologie
Centre Hospitalier Universitaire de Reims (CHU Reims)
Laboratoire de génétique
Service des maladies du sang
PhG from Plateforme SNP, Transcriptome & Epigénomique received a grant from La Ligue Contre le Cancer/Comité Départemental 49 to support this work.
Source :
BMC Medical Genomics, BMC Medical Genomics, 2012, 5 (1), pp.6. ⟨10.1186/1755-8794-5-6⟩, BMC Medical Genomics, BioMed Central, 2012, 5 (1), pp.6. ⟨10.1186/1755-8794-5-6⟩, BMC Medical Genomics, Vol 5, Iss 1, p 6 (2012)
Publication Year :
2012
Publisher :
HAL CCSD, 2012.

Abstract

Background Gene expression profiling has shown its ability to identify with high accuracy low cytogenetic risk acute myeloid leukemia such as acute promyelocytic leukemia and leukemias with t(8;21) or inv(16). The aim of this gene expression profiling study was to evaluate to what extent suboptimal samples with low leukemic blast load (range, 2-59%) and/or poor quality control criteria could also be correctly identified. Methods Specific signatures were first defined so that all 71 acute promyelocytic leukemia, leukemia with t(8;21) or inv(16)-AML as well as cytogenetically normal acute myeloid leukemia samples with at least 60% blasts and good quality control criteria were correctly classified (training set). The classifiers were then evaluated for their ability to assign to the expected class 111 samples considered as suboptimal because of a low leukemic blast load (n = 101) and/or poor quality control criteria (n = 10) (test set). Results With 10-marker classifiers, all training set samples as well as 97 of the 101 test samples with a low blast load, and all 10 samples with poor quality control criteria were correctly classified. Regarding test set samples, the overall error rate of the class prediction was below 4 percent, even though the leukemic blast load was as low as 2%. Sensitivity, specificity, negative and positive predictive values of the class assignments ranged from 91% to 100%. Of note, for acute promyelocytic leukemia and leukemias with t(8;21) or inv(16), the confidence level of the class assignment was influenced by the leukemic blast load. Conclusion Gene expression profiling and a supervised method requiring 10-marker classifiers enable the identification of favorable cytogenetic risk acute myeloid leukemia even when samples contain low leukemic blast loads or display poor quality control criterion.

Details

Language :
English
ISSN :
17558794
Database :
OpenAIRE
Journal :
BMC Medical Genomics, BMC Medical Genomics, 2012, 5 (1), pp.6. ⟨10.1186/1755-8794-5-6⟩, BMC Medical Genomics, BioMed Central, 2012, 5 (1), pp.6. ⟨10.1186/1755-8794-5-6⟩, BMC Medical Genomics, Vol 5, Iss 1, p 6 (2012)
Accession number :
edsair.doi.dedup.....a1426070f79fb6f7773a4d09598e08b3